ARTICLE | Distillery Therapeutics


January 8, 2018 9:53 PM UTC

Cell culture and mouse studies suggest inhibiting DNA synthesis at depurinated (abasic) sites could help treat temozolomide-resistant glioblastoma multiforme (GBM). In three human temozolomide-resistant GBM cell lines, temozolomide plus a previously reported artificial nucleoside that inhibits DNA synthesis at sites depurinated by temozolomide increased cell death and apoptosis compared with either agent alone. In a xenograft mouse model of temozolomide-resistant GBM, the artificial nucleoside plus temozolomide decreased tumor growth and increased survival. Next steps by Red5 Pharmaceuticals LLC include toxicology studies of the artificial nucleoside...